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Adhesion to extracellular matrix regulates cell survival through both integrin engagement and appropriate cell spreading. Numerous
signaling pathways converge to affect the levels and posttranslational modifications of Bcl-2 family proteins. Recent work has defined
specific roles for different Bcl-2 proteins in the disruption of mitochondrial function that leads to cell death. Using this understanding of Bcl-2
protein function as a framework, we will consider the molecular mechanisms of apoptosis induced by integrin detachment (anoikis) and cell
death stimulated by the loss of cytoskeletal architecture (amorphosis).
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In multicellular organisms, survival of many cell types
depends on adhesion to specific extracellular matrix pro-
teins [1–3]. Detachment of cells from the extracellular
matrix often results in apoptotic cell death, known as
anoikis [2], which is derived from the Greek word for
‘‘homelessness’’. Anoikis plays an important role in the
physiological induction of apoptosis during development
and maintenance of tissue organization and homeostasis in
the organism. For example, inner endodermal cells lose
adhesion to extracellular matrix and undergo anoikis during
vertebrate embryogenesis, which permits cavitation to occur
[4]. Widespread proteolysis of the extracellular matrix
causes anoikis of mammary epithelial cells in vivo, which
contributes to the involution of the mammary gland [5]. In
the gut, intestinal epithelial cells lose anchorage as they
reach the luminal surface of the crypt, undergo anoikis, and
are released into the intestinal lumen [6]. There is evidence
that skin keratinocytes also undergo anoikis as they lose0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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shed from the skin [7].
Resistance to anoikis is thought to play a central role in
tumor progression and metastatic spread. Most cell lines
derived from solid tumors will grow in an anchorage-
independent manner in soft agar or suspension culture [8],
and experimental evidence demonstrates that suppression
of resistance to anoikis in transformed cells strongly
inhibits their tumorigenicity in vivo [9]. Conversely, in
vitro selection for anoikis-resistant cells increases the in
vivo tumorigenicity of intestinal epithelial cells [10] and
the metastatic capacity of melanoma cells [11] in mouse
model systems. Rescuing human breast tumor cell lines
from anoikis through overexpression of either Bcl-2 or
Bcl-xL also increases their metastatic potential [12]. In-
sensitivity to anoikis may allow tumor cells to tolerate the
alterations in extracellular matrix that often accompany
tumor development and progression [13]. Although tumor
cells are often resistant to anoikis, the persistent sensitivity
of tumor-associated endothelial cells to anoikis has allowed
the development of novel cancer therapies. Disrupting
endothelial cell binding to extracellular matrix with either
antibody [14] or small molecule [15] antagonists causes
tumor regression by stimulating anoikis in the endothelial
cells that provide vascularization of the tumor. Anoikis
also seems to play a role in other disease states, particu-
larly fibrotic conditions where excessive or inappropriate
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for anoikis in maintaining tissue architecture [16].
Cellular attachment to the extracellular matrix is medi-
ated by the integrin class of heterodimeric transmembrane
receptors. Integrins serve as a direct physical link between
the extracellular matrix and the intracellular actin cyto-
skeleton [17], through multiprotein complexes, known as
focal adhesions [18]. Engagement of integrin receptors
results in cell spreading which depends on both the
integrity and dynamic rearrangement of actin microfila-
ments [19]. In endothelial cells, survival after attachment
to extracellular matrix requires not only integrin engage-
ment, but subsequent cell spreading [20,21]. Direct dis-
ruption of actin-mediated cell spreading also stimulates
apoptosis in epithelial cells that remain attached to extra-
cellular matrix [22–24]. These findings suggest that adop-
tion of a specific cellular morphology is required for
survival. For the purposes of this review, we will refer
to apoptotic cell death that is induced specifically through
the disruption of cell shape as amorphosis, which is
derived from the Greek word amorphos for ‘‘lack of
shape’’ or ‘‘misshapen’’.
Disruption of mitochondrial function is one of the hall-
marks of apoptosis [25,26]. Loss of mitochondrial mem-
brane potential and release of cytochrome c leads to
activation of Apaf-1, which activates the cysteine proteases,
caspase-9 and caspase-3. Cleavage of cellular substrates by
these caspases constitutes the ‘‘execution’’ phase of apopto-
sis, which is characterized by membrane blebbing, nuclear
condensation and DNA fragmentation. Inhibition of cas-
pases or genetic deficiency in Apaf-1, caspase-3 or caspase-Fig. 1. Domain structure of Bcl-2 family proteins involved in anoikis and amorph
shown schematically, with the approximate position of Bcl-2 homology (BH) do9 can prevent many of the cellular changes associated with
apoptosis, but does not rescue cell viability [27,28]. The loss
of mitochondrial function therefore represents a commit-
ment point of the cell to death.
The Bcl-2 family of proteins are important regulators
of mitochondrial membrane potential and permeability
[29]. Recent work has helped define specific signaling
roles for the different members of the Bcl-2 family
[27,30]. We will consider the current molecular under-
standing of apoptosis by either detachment (anoikis) or
disruption of cell spreading (amorphosis), specifically
with regard to the ultimate effect on signaling by Bcl-2
proteins.2. Regulation of mitochondrial function by Bcl-2 family
proteins
The Bcl-2 proteins comprise a protein family of at least
22 members, related through their conservation of a-helical
sequences, known as Bcl-2 homology (BH) domains [29].
For simplicity, we will focus on those Bcl-2 proteins which
play a known role in cell death induced by disruption of
extracellular matrix contact (Fig. 1). The antiapoptotic
proteins, Bcl-2 and Bcl-xL, contain all four known BH
domains, and promote cell survival by binding proapoptotic
Bcl-2 proteins and inhibiting their function. The proapop-
totic Bcl-2 proteins can be separated into two classes, the
first being the multidomain proteins Bax and Bak, which
contain only the first three BH domains. The second class of
proapoptotic Bcl-2 proteins are the BH3-only proteins (Bid,osis. Antiapoptotic and apoptotic members of the Bcl-2 protein family are
mains and transmembrane (TM) domains indicated.
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diverse, sharing only the single BH3 domain [31].
The multidomain proapoptotic proteins, Bax and Bak,
are the only Bcl-2 proteins capable of directly disrupting
mitochondrial function [29]. Either Bax or Bak can homo-
oligomerize into pore-forming complexes that permeabilize
the outer mitochondrial membrane [29,32], leading to re-
lease of cytochrome c and activation of apoptotic caspases
(Fig. 2). Oligomerization of Bak is regulated, but it is
constitutively localized to the outer mitochondrial mem-
brane [33]. Bax is often found in the cytosol in viable
epithelial cells, and is regulated both through translocation
to the mitochondria and subsequent oligomerization [34,35].
Recent evidence suggests that Bax can form oligomers of
many subunits, and that these large complexes may be
necessary for permeabilization of the outer mitochondrial
membrane in epithelial cells [36,37]. Mouse embryo fibro-
blasts which are deficient in both Bax and Bak are resistant
to a wide range of apoptotic stimuli, confirming the critical
role of these two proteins in mitochondrially induced cell
death [27].
The BH3-only proteins have recently been separated
into two distinct classes, through studies measuring the
effects of the BH3 domain peptides on isolated mitochon-
dria [30]. Bid and Bim have been termed ‘‘activators’’,
since they are capable of binding directly to the proapop-Fig. 2. Bcl-2 protein function at the mitochondrial membrane. Multidomain a
permeabilizing the outer mitochondrial membrane during cell death. Multimerizat
and activation of executioner caspases. The pore-forming activity of Bax and
Antiapoptotic Bcl-2 proteins (Bcl-2 and Bcl-xL) can associate with Bax and Bak a
binding the ‘‘activators’’, Bid and Bim. The BH3-only ‘‘sensitizer’’ proteins (Bad
proteins from binding to Bcl-2 or Bcl-xL, enhancing ‘‘activator’’ function towardtotic Bax and Bak proteins and inducing release of
cytochrome c. Bad and Bik, on the other hand, bind
preferentially to Bcl-2 and Bcl-xL and are incapable of
inducing activation of Bax and Bak. Binding of Bad or
Bik displaces the activators Bid or Bim from associating
with the antiapoptotic proteins Bcl-2 or Bcl-xL. Conse-
quently, this liberates Bid and Bim to activate the apo-
ptotic function of Bax and Bak. The BH3-only proteins
Bad and Bik have been termed ‘‘sensitizers’’, as they
block the ability of antiapoptotic Bcl-2 proteins to seques-
ter activators, thereby enhancing the death-promoting
effects of Bid and Bim. The specific classification of
the BH3-only protein, Bmf, remains undetermined. The
protein sequence of the BH3 domain of Bmf bears the
most similarity to Bid and Bim, suggesting it may be an
activator [30,38]. However, yeast two-hybrid and co-im-
munoprecipitation experiments show that Bmf binds Bcl-2
and Bcl-xL, but not Bax, suggesting a role as a sensitizer
[38].
Overexpression of either Bcl-2 or Bcl-xL can prevent
epithelial cell death upon disruption of extracellular matrix
contact, whether during anoikis following detachment
[2,39], or amorphosis after cytoskeletal disruption [24].
Protection by Bcl-2 and Bcl-xL is thought to occur through
either sequestering of BH3-only activators or association
with the pore-forming proteins Bax and Bak. Recent datapoptotic proteins (Bax and Bak) are the only Bcl-2 proteins capable of
ion of either Bax or Bak results in pore formation, release of cytochrome c
Bak is stimulated by the BH3-only ‘‘activator’’ proteins (Bid and Bim).
nd prevent their pore-forming ability, or indirectly inhibit pore formation by
and Bik) cannot stimulate pore-formation directly, but displace ‘‘activator’’
Bax and Bak.
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only proteins [27] was incapable of preventing anoikis in
mammary epithelial cells, despite binding to Bax [40]. The
protective effect of the multidomain antiapoptotic Bcl-2proteins may therefore be primarily through their effect on
the signaling of BH3-only proteins. Adhesion and spreading
of cells on extracellular matrix alters both the levels and
activities of Bcl-2 family proteins, which can affect the
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determine the life or death of the cell. There are multiple
mechanisms of Bcl-2 protein regulation by integrins, which
could be a reflection of cell-type specificity in the signaling
pathways. We will first examine what is known about
transcriptional regulation of the Bcl-2 proteins by attach-
ment to extracellular matrix and then consider the role of
appropriate cell spreading (Fig. 3).3. Transcriptional regulation of Bcl-2, Bax and Bim by
integrin engagement
Integrin-mediated attachment to extracellular matrix
increases the level of Bcl-2 protein, and this survival effect
is mediated largely through enhanced transcription of the
Bcl-2 gene [41,42]. Conversely, detachment of endothelial
cells from extracellular matrix enhances transcription of
both cell cycle arrest and apoptosis genes through activa-
tion of p53 [43]. Transcription of the proapoptotic protein,
Bax, is directly regulated by p53 in murine leukemia cells
and the resulting increase in Bax protein can tip the balance
of the Bcl-2/Bax ratio toward cell death [44,45]. Fibroblasts
which are deficient in p53 are resistant to anoikis, and are
more metastatic when injected into the tail vein of mice
[46]. The resistance to anoikis in p53-deficient fibroblasts is
presumably mediated through the resulting loss of Bax
induction, since this effect can be mimicked by overex-
pression of Bcl-2 [46]. Residual p53-dependent cell cycle
arrest can reduce the outgrowth of metastatic lesions from
Bcl-2 overexpressing fibroblasts, but the resistance to
anoikis induced by Bcl-2 overexpression does enhance
tumor cell survival in the blood circulation [47]. Epithelial
cells may have additional p53-independent pathways to
induce apoptosis, because acute suppression of p53 actually
enhances apoptosis when primary mammary epithelial cells
are growing in a polarized manner on extracellular matrix
[48].
Recent data demonstrate that transcription of the BH3-
only protein, Bim, is increased following detachment of
immortalized mammary epithelial cells from extracellular
matrix, but the levels of other BH3-only proteins are not
altered [40]. Transcriptional regulation of Bcl-2 family
members by extracellular matrix therefore appears to occurFig. 3. A model of signaling from integrins and the cytoskeleton to Bcl-2 family
with an organized actin cytoskeleton, activates FAK autophosphorylation. Signalin
Ras–MAPK pathway by recruiting Grb2-Sos. Activation of Ras–MAPK and its
many stages, either through transcription (trx) or by phosphorylation (yellow, nu
inhibiting caspase-8. ILK, PI3K and PAK coordinate to inactivate Bad by phospho
in an inactive conformation in the cytoplasm, while Bim and Bmf are sequeste
cytoskeletal disorganization results in loss of the survival signals described in pane
growth factor receptor (EGFR) protein downregulates Ras–MAPK and PI3K, as do
unligated integrins cleaves Bid to its active form (tBid). Bim and Bmf are liberated
(Bim sites numbered relative to BimEL). Bax is upregulated by p53-dependent tran
mitochondria. Phosphorylation of Bad is lost, allowing it to inhibit Bcl-2/Bcl-xL
releases cytochrome c from the mitochondria, committing the cell to death.primarily with Bcl-2, Bax and Bim, but numerous posttran-
scriptional and posttranslational effects on Bcl-2 proteins are
also observed during anoikis.4. Movement of Bax and Bid during anoikis
Fusion of Bax to green fluorescent protein demonstrated
that induction of apoptosis leads rapidly to the movement of
Bax from the cytosol to mitochondria [35]. Detachment of
mammary epithelial cells from extracellular matrix also
causes translocation of Bax to mitochondria, concurrent
with a conformational change that exposes the BH3 domain
[34]. These changes in Bax precede activation of caspases,
including initiator caspases, such as caspase-8 [49]. Since
oligomers of Bax are capable of directly permeabilizing the
outer mitochondrial membrane, this event may seem to be
sufficient to induce cytochrome c release and anoikis [29].
However, in apoptotically resistant human neuroblastoma
cells, cytotoxins also led to a conformational change in Bax
and its translocation to mitochondria, but cytochrome c
release was not observed [50]. Mitochondrially localized
Bcl-2 or Bcl-xL can antagonize the pore-forming ability of
Bax [29], so signaling by BH3-only protein sensitizers and
activators may still be required to neutralize the survival
effect of Bcl-2/Bcl-xL and promote efficient Bax-dependent
pore formation.
Detachment can stimulate caspase-8 in epithelial cells
[51,52], which is known to cleave the activator, Bid, to a
truncated form, tBid. Resulting exposure of a glycine motif
at the cleavage site leads to myristoylation of tBid and
enhances its localization to mitochondria [53]. tBid can then
induce the release of cytochrome c, but fails to do so in Bax/
Bak-deficient fibroblasts, indicating that tBid functions by
activating the pore-forming ability of Bax/Bak [32,54,55].
The BH3 domain of tBid is not required for its localization
to mitochondria, but is required to induce release of cyto-
chrome c by Bax/Bak [32]. Since Bcl-2 or Bcl-xL can bind
and sequester the BH3 domain of tBid [27], additional
control over anoikis exists even following mitochondrial
translocation of both Bax and tBid. Phosphorylation can
regulate the activity of the BH3-only proteins, Bad, Bim and
Bik, as well as Bcl-2, and the kinases responsible are often
regulated by the binding of integrins to extracellular matrix.proteins. (A) Integrin-mediated attachment to extracellular matrix, together
g from FAK, Shc and growth factor receptors combine to fully activate the
reinforcement by Cas-mediated activation of PAK affects Bcl-2 function at
mbered by amino acid). Transcription of cFLIP prevents Bid cleavage by
rylation which results in its sequestration by 14–3–3 proteins. Bax remains
red to microtubules and actin filaments, respectively. (B) Detachment or
l A, as well as the induction of specific apoptotic signals. Loss of epidermal
es the loss of focal adhesion signaling. Caspase-8 activation by either Fas or
from their cytoskeletal sequestration and activated by JNK phosphorylation
scription, but also undergoes a rapid conformational change and localizes to
. Resulting multimerization of Bax/Bak, and activation by Bim and tBid,
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protein phosphorylation
Ligation of integrins results in activation of numerous
intracellular signaling pathways, and the ligand binding
status of integrins also regulates growth factor signaling.
Thus, signal transduction by growth factor receptors is
attenuated in cells detached from extracellular matrix
[56,57]. A number of studies have demonstrated mecha-
nisms by which integrin-dependent adhesion serves to
recruit and activate proteins involved in transmitting growth
factor signals (reviewed in Refs. [58,59]). While integrins
affect cell cycle progression, gene expression and motility at
many levels, we will primarily consider how integrin-
dependent activation of MEK, JNK or PI3K/Akt/PAK
modulates Bcl-2 protein function by direct phosphorylation.
5.1. MEK
Binding of integrins to extracellular matrix leads to the
assembly of multiprotein complexes, known as focal adhe-
sions, which connect integrin cytoplasmic domains to the
actin cytoskeleton [18]. In addition to this physical role,
focal adhesions play an important role in integrin signaling
that protects cells against anoikis. Constitutive activation of
the focal adhesion kinase (FAK) [60] can render epithelial
cells resistant to anoikis and increase their tumorigenic
capacity [61]. Loss of FAK signaling induces apoptosis in
a p53-dependent manner [62]. During fibroblast attachment,
FAK autophosphorylates and activates c-Src to respond by
phosphorylating tyrosine 925 of FAK [63,64]. This site has
been reported to serve as a binding site for the SH2 domain
of Grb2-Sos, leading to GTP exchange on p21-Ras and
recruitment of Raf, which phosphorylates and activates the
kinase, MEK [65,66]. Tyrosine phosphorylation of Shc also
promotes recruitment of the Grb2/Sos complex to the
plasma membrane, thereby activating Ras, Raf, MEK and
the MAPK cascade in response to integrin-mediated cell
attachment [67].
Increased MEK activity impacts Bcl-2 family members
in several ways. First, MEK mediates phosphorylation of
serine-112 of Bad, leading to its release from Bcl-2 and Bcl-
xL [68,69]. This effectively removes the apoptosis-sensitiz-
ing function of Bad, since Bcl-2 and Bcl-xL are now free to
associate with Bax/Bak and sequester activator Bcl-2 family
proteins, Bim and Bid. MEK-dependent activation of
MAPK1/2 also leads to phosphorylation of Bcl-2 at multiple
sites, preventing ubiquitin-mediated destruction of Bcl-2
[70]. MEK signaling is also important for suppressing
transcription of Bim. Loss of MEK signaling through
downregulation of the EGF receptor following mammary
epithelial cell detachment stimulates anoikis, in part, by
increasing Bim expression [40]. Constitutive activation of
MEK can reduce anoikis by preventing induction of Bim
[40]. Oncogene-mediated stimulation of the Ras–Raf–
MEK pathway can promote resistance to anoikis by inacti-vating Bad and protecting Bcl-2 through phosphorylation,
and suppressing Bim transcription. In untransformed cells,
full activation of MEK in response to integrin engagement
requires reinforcement by PI3K, Akt and PAK [71–74], and
these proteins can also affect Bcl-2 protein signaling directly
at several levels.
5.2. PI3K/Akt/PAK
Adhesion to extracellular matrix activates the integrin-
linked kinase (ILK) in epithelial cells, which can prevent
anoikis when activated constitutively [75,76]. Signaling by
ILK, FAK and growth factor receptors likely all contribute
to integrin-dependent activation of PI3K, and the resulting
3,4,5-PIP3 lipid product can then serve to recruit and
activate Vav [77–79], which catalyzes GTP exchange on
p21-Rac [80,81]. FAK also regulates adhesion-dependent
Rac activation by promoting the p130-Cas/Crk complex,
which stimulates the novel guanine nucleotide exchange
factor DOCK180 [82–84]. In addition to inducing actin
rearrangement and cell spreading, p21-Rac stimulates the
kinase PAK [85], which feeds back directly on the Ras–
MAPK pathway by phosphorylating and activating both Raf
and MEK [71,74]. An additional integrin-dependent feed-
back from PAK to the MAPK pathway may occur through
FAK. Phosphorylation of p130-Cas by FAK induces its
association with the adapter protein Nck in fibroblasts
[86]. Association of Nck and PAK in fibroblasts is integ-
rin-dependent [87], and together with PI3K-dependent acti-
vation of Rac, likely allows reinforcing feedback to Raf and
MEK. In support of this model, activation of Raf following
fibroblast adhesion to fibronectin requires both PI3K and
PAK signaling [88]. Association of the focal adhesion
protein, paxillin, with PAK [89] and the Rac exchange
factor, PIX [90], provides yet another mechanism for
integrin signaling to enhance MAPK signaling.
In addition to reinforcing the Ras–MAPK pathway, ILK
and PI3K cooperate to activate Akt. In prostate tumor cells,
ILK has been reported to phosphorylate Akt at serine-473,
while PI3K-dependent activation of PDK-1 leads to phos-
phorylation of Akt at serine-308 [91]. Phosphorylation of
both serine-308 and serine-473 is required for full activation
of Akt [91]. Overexpression of Akt can suppress anoikis in
epithelial cells [92], as well as apoptosis induced by
expression of the Bcl-2 proteins, Bax, Bak, Bik or Bad in
rat fibroblasts [93]. In intestinal epithelial cells, part of the
protective effect of Akt can be traced to its ability to
stimulate NFnB-dependent transcription of the antiapoptotic
proteins, Bcl-2 and Bcl-xL [94,95]. More importantly, Akt
protects from apoptosis by phosphorylating serine-136 of
Bad in neurons [96]. Mutation of this site in Bad prevents
the ability of Akt to enhance survival in rat fibroblasts [93].
Bad associates with 14–3–3 proteins after MEK-dependent
phosphorylation at serine-112 and Akt-dependent phosphor-
ylation of serine-136 [97]. Binding to 14–3–3 proteins both
sequesters Bad in the cytoplasm, and enhances phosphory-
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bind Bcl-2 [97]. PAK can also phosphorylate both serine-
112 and -136 of Bad in fibroblasts, providing a parallel
input to suppress anoikis [98].
Signaling by ILK, FAK, PI3K, Akt, PAK and MEK
therefore combine to enhance survival, through both tran-
scriptional responses and phosphorylation of Bad. In this
regard, it is interesting to note that p53-dependent transcrip-
tion of the lipid phosphatase PTEN can block this survival
pathway at several points, and promote apoptosis. PTEN
can inhibit PI3K signaling by dephosphorylating 3,4,5,-
PIP3, but can also directly dephosphorylate FAK [99,100].
Since PI3K and FAK are essential for integrin-mediated
activation of Akt and MEK, it is understandable that
expression of PTEN can suppress integrin survival path-
ways. Conversely, loss of PTEN removes an important
negative control on this survival pathway and contributes
to anchorage-independence in tumor cells [99,101].
5.3. JNK
The specific role of kinase signaling by another MAP
kinase, JNK, in anoikis is a little less clear. JNK is activated
during anoikis in epithelial cells, and blockade of JNK
signaling can protect from cell death following detachment
[102]. JNK-mediated phosphorylation of Bim and Bmf
releases these BH3-only proteins from their cytoskeletal
associations, and promotes cell death via Bax/Bak [103].
Similarly, phosphorylation of Bim at serine-65 by JNK
enhances activation of Bax, and JNK can stimulate in-
creased transcription of Bim in neuronal cells [104]. How-
ever, epithelial anoikis can be prevented with a broad
spectrum caspase inhibitor or by expressing activated
PI3K or Akt, without affecting JNK activation [105].
Additionally, integrin engagement has been shown to acti-
vate JNK [106], and FAK-dependent activation of JNK is
actually linked with protection from cell death and cell cycle
progression [107,108].
Differences in the cell types and serum conditions used in
these studies, as well as in the kinetics and duration of JNK
activation, may explain the differences in the observed
results. It is also interesting to note that the ability of JNK
to induce epithelial anoikis apparently depends on caspase
activation [102]. Very recent data show that apoptotic
induction leads to caspase-dependent cleavage of the car-
boxy-terminal 14 amino acids from JNK in human leukemia
cells [109]. While this does not apparently alter the kinase
activity of JNK, it is proposed to potentially change its
substrate specificity [109]. Since this cleavage only leads to
a minor shift in the mobility of the protein from 54 to 52
kDa, it may have been overlooked in previous studies. Full-
length JNK could promote survival following integrin
engagement, while the caspase-truncated form may select
different substrates during anoikis. This could potentially
reconcile the disparate data on the role of JNK activation in
anoikis, but further testing of this model is clearly required.6. Death receptor signaling
The potential role of death receptor signaling in anoikis
varies somewhat by cell type. Detachment of endothelial
cells from extracellular matrix results in transcriptional
upregulation of Fas receptor and Fas–Fas ligand interaction
[110]. In addition, execution of apoptosis can be blocked by
antibodies that inhibit Fas receptor signaling [110]. Binding
of Fas ligand to the Fas receptor results in receptor cluster-
ing and the recruitment of the adapter protein FADD and
caspase-8 to the cytoplasmic domain of the receptor. Anoi-
kis in endothelial cells, MCF10A mammary epithelial cells
or MDCK kidney epithelial cells leads to the activation of
caspase-8 [39,52,110]. Furthermore, epithelial anoikis can
be blocked by dominant negative forms of either FADD or
caspase-8 [39]. As noted above, activated caspase-8 cleaves
the Bcl-2 protein, Bid, and enhances its localization to
mitochondria where it activates apoptosis through Bax/
Bak [53]. Bid cleavage is observed during anoikis in MDCK
cells [51]. As a counterbalance to this effect, attachment-
mediated activation of MEK upregulates transcription of c-
FLIP, at least in endothelial cells, which directly inhibits of
caspase-8 [110]. Overexpression of either Bcl-2 or Bcl-xL
can block activation of caspase-8 during anoikis [39],
demonstrating that mitochondrial events still control death
receptor signaling after detachment.
However, there are certainly death receptor-independent
models of anoikis. In numerous cell types, unligated integrin
receptors directly activate caspase-8, without the involve-
ment of death receptors [111]. In FSK-7 mouse mammary
epithelial cells, many of the early events of anoikis occur
independently of caspase-8 activation [49]. This includes
Bax conformational change, translocation to mitochondria
and subsequent release of cytochrome c [49]. In addition, no
cleavage of Bid is observed in this system. It is worth noting
that many of the measurements of apoptosis in these studies
rely on the quantification of apoptotic nuclear morphology.
Overexpression of Bcl-2 prevents cell death induced by
actin cytoskeletal disruption in mammary epithelial cells,
but does not prevent nuclear condensation [24]. It is
possible that changes in nuclear morphology are not always
indicative of apoptotic execution, especially in systems such
as anoikis and amorphosis, where cell shape change already
occurs as part of the apoptotic stimulus. However, the
caspase-8-independent induction of cytochrome c release
in these studies is compelling, since this is thought to be a
commitment step to cell death. Chemical inhibition of
caspases [28,112,113] or genetic deficiency in caspase
activation downstream of mitochondria [27] can prevent
many of the morphological and biochemical indications of
apoptosis, without rescuing clonogenic cell survival. This is
presumably due to permanent damage to the mitochondria
that follows release of cytochrome c. With this in mind, it
will also remain important to measure clonogenic cell
survival in studies addressing the role of caspase-8 in
anoikis, since earlier studies have relied on measurement
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pases can prevent many hallmarks of apoptosis, including
DNA fragmentation, but does not necessarily rescue cell
viability [28,112,113]. It is possible that caspase-8 activation
plays a role in apoptotic execution, even though early
release of cytochrome c by Bax has already committed
these cells to death. So, although cell type differences may
be responsible for some of the variable findings on the
involvement of death receptors in anoikis, a direct compar-
ison of the experimental systems at the level of clonogenic
cell survival may still resolve some of the differences.
Measuring the endpoint of cell survival remains important
in any apoptosis study to determine whether observed
changes in signaling events have consequences for the
cellular phenotype.7. Cytoskeleton-dependent cell spreading and
amorphosis
Following engagement of extracellular matrix by integ-
rins, cells spread through rearrangement of the actin cyto-
skeleton by Rho proteins [114–116]. Many of the signaling
pathways we have considered for their role in cell survival
also regulate cell spreading. Inhibiting the function of either
FAK, PI3K or MEK can inhibit cell spreading [73,117,118].
Interestingly, cell spreading itself seems to feedback on cell
survival signaling. Elegant experiments using micropat-
terned extracellular matrix showed that, even after integrin
binding, endothelial cell spreading is actually essential to
suppress apoptosis [20,21]. Three-dimensional morphogen-
esis of mammary epithelial cells in gels of extracellular
matrix is also required to prevent cell death [119,120].
Normal epithelial architecture is maintained and malignant
growth suppressed by the induction of apoptosis upon loss
of appropriate cell morphology, which we term amorphosis.
Stable cellular morphology is promoted through a dy-
namic balance of counteracting actin and microtubule fila-
ments, known as tensegrity [17,121,122]. Contractile force,
applied to integrin contacts by the actin cytoskeleton, is
sensitive to the rigidity of the extracellular matrix, and loss
of rigidity in the matrix results in rapid disassembly of actin
filaments, even though integrin receptors remain engaged
[123–125]. For this reason, loss of actin organization could
serve as a signal for disrupted extracellular matrix contact.
Even after attachment and spreading, persistent maintenance
of cytoskeletal architecture is required to prevent amorpho-
sis. Reflecting the dynamic nature of cytoskeletal filaments,
amorphosis can be induced when filaments are either
depolymerized or stabilized artificially. Inhibition of actin
polymerization with Cytochalasin D or Latrunculin-A leads
to amorphotic cell death [22,24,126]. Overexpression of
either Bcl-2 or Hsp-27 can prevent cell death in these cases,
as can loss of p53, confirming that amorphosis represents a
programmed process rather than nonspecific cytotoxicity.
Stabilization of actin filaments by jasplakinolide also indu-ces amorphosis in lung epithelial cells [127]. Similarly,
depolymerization of microtubules with vincristine or stabi-
lization with paclitaxel leads to amorphosis in mammary
carcinoma cells, which can be inhibited by overexpression
of Bcl-2 [128]. The molecular mechanisms by which
amorphosis affects Bcl-2 proteins are not completely under-
stood, but could involve either disruption of integrin-medi-
ated signaling pathways or specific cytoskeletal sensors.
Actin depolymerization or inhibition of Rho-dependent
actin organization prevents integrin-stimulated FAK phos-
phorylation in platelets [129]. Raf, even when targeted to
the plasma membrane, is not activated when actin is
depolymerized in fibroblasts [130]. Both of these effects
would impact integrin-mediated stimulation of the MEK
signaling pathway. There is also evidence that actin-medi-
ated signaling provides a constant input to the MEK
pathway during adhesion to extracellular matrix. Activation
of PKA upon cell detachment downregulates PAK signal-
ing, and activation of Raf and MEK [72]. Inhibiting PKA
leads to sustained MEK signaling in suspension, although
depolymerization of actin blocks the adhesion-independent
stimulation of MEK, suggesting an active role for actin
polymerization in maintaining MEK activity [72]. As dis-
cussed in the previous sections, FAK and MEK signaling
impact Bcl-2 protein signaling at multiple points. Interest-
ingly, while integrin-mediated MEK activation is inhibited
by Cytochalasin D, integrin-dependent activation of p70-S6
kinase is not affected, indicating that some pathways are
actin-dependent and others are not [131]. Tyrosine phos-
phorylation of p130-Cas in fibroblasts is also dependent on
a polymerized actin cytoskeleton, although this requirement
is overcome by oncogenic v-Src [132]. This provides one
possible mechanism by which an oncogene could promote
survival despite cytoskeletal disorganization, as is seen with
the amorphotic resistance of the metastatic mammary cell
line, MDA-MB-453 [24].
Although downregulation of FAK-mediated signaling
could partially explain the affect of actin depolymerization
to induce amorphosis, microtubule depolymerization actu-
ally enhances focal adhesion assembly and FAK phosphor-
ylation [133,134], and must operate by a distinct mechanism
to induce amorphosis. A separate pathway is also supported
by the finding that p53 deficiency in fibroblasts actually
increases apoptosis after microtubule disruption [135], de-
spite protecting from cell death after actin depolymerization
[22]. Microtubule damage induces JNK-dependent phos-
phorylation of Bcl-2, which is not observed following DNA
damage [128,136], demonstrating that amorphosis is mech-
anistically distinct from apoptosis induced by DNA damage.
Signaling by death receptors is also affected by disrup-
tion of the cytoskeleton. Stabilization of microtubules with
paclitaxel induces amorphosis in a manner that depends on
signaling by the Fas receptor [137]. Paclitaxel may mediate
this effect through upregulation of Fas-L, which is also
observed following treatment with Cytochalasin D [137].
Disruption of actin filaments may also directly activate the
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[138].
In addition to the effects of cytoskeletal disruption on
receptor signaling pathways, Bcl-2 proteins may play a
direct role as sensors of cytoskeletal integrity. The BH3-
only protein, Bim, is bound to the dynein light chain
(DLC1) and sequestered to the microtubule cytoskeleton
[139]. Treatment with paclitaxel releases Bim from its
binding to microtubules and it translocates to mitochondria
after diverse apoptotic stimuli [38,139]. This response is
independent of caspase activation, suggesting that Bim may
represent a direct sensor of microtubule integrity [139]. Bim
can directly stimulate cytochrome c release by binding Bax/
Bak [30], and should induce cell death unless counteracted
by free Bcl-2 survival proteins. Cell detachment increases
expression of Bim in mammary epithelial cells [40], poten-
tially enhancing the sensitivity to any microtubule irregu-
larities in suspended cells. Increased susceptibility of
suspended mammary carcinoma cells to apoptosis induced
by paclitaxel supports this model [140]. Another BH3-only
protein, Bmf, binds DLC2 and is localized to the actin
cytoskeleton through association with the myosin V motor
complex [38]. Depolymerization of actin filaments releases
Bmf from its cytoskeletal sequestration, and cell detachment
induces movement of Bmf to mitochondria and association
with Bcl-2 [38]. As noted above, the specific classification
of Bmf as a BH3-only activator or sensitizer is currently
undetermined. Both Bim and Bmf can be released from their
cytoskeletal localizations by JNK-mediated phosphorylation
[103], and this provides a potential point of crosstalk
between these cytoskeletal sensors and integrin-stimulated
JNK signaling. Bim and Bmf may serve as direct modu-
lators of amorphosis by monitoring cytoskeletal integrity,
and regulation of either the level or phosphorylation state of
these BH3-only proteins may modulate cellular sensitivity
to cytoskeletal abnormalities.8. Conclusions
Cell adhesion regulates cell survival by altering the
signaling balance between antiapoptotic and proapoptotic
members of the Bcl-2 protein family. Loss of integrin
binding to extracellular matrix results in anoikis, while
disruption of a defined cell shape commits cells to death
by amorphosis. Either apoptotic pathway results from a loss
of survival signals produced by attachment or spreading,
combined with the specific induction of death regulators by
detachment or cytoskeletal disruption. Independence from
anoikis may enhance tumor metastasis by allowing cells to
survive detachment from the extracellular matrix of their
organ of origin. Resistance to amorphosis may allow tumor
cells to tolerate the gross disruptions of cytoskeletal orga-
nization that are commonly observed in solid tumors, and
provide protection against apoptosis induced by microtu-
bule-directed chemotherapeutic agents, such as paclitaxel.The specific contributions of anoikis and amorphosis to
tumor metastasis remain to be separated from a general
resistance to apoptosis, since metastatic enhancement by
p53 loss and overexpression of Bcl2/BclxL [46,47] allows
tumor cells to escape a fairly broad range of apoptotic
stimuli. Identification of the cytoskeletally regulated BH3-
only proteins Bim and Bmf [38,139], as well as modifica-
tions to Bcl-2 that occur with microtubule disruption but not
DNA damage [128,136], may allow more specific questions
on the roles of anoikis and amorphosis in tumor progression
and metastasis in the near future.Acknowledgements
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